Pseudobulbar affect: Difference between revisions

From WikiMD's Wellness Encyclopedia

Newer edit →
No edit summary
 
CSV import
Line 1: Line 1:
{{Infobox medical condition
| name = Pseudobulbar Affect
| image =
| caption =
| field = Neurology
| symptoms = Involuntary laughing or crying
| complications = Social embarrassment, depression
| onset =
| duration =
| causes = Neurological disorders
| risks =
| diagnosis = Clinical evaluation
| treatment = Medication, therapy
| frequency =
}}
'''Pseudobulbar affect''' (PBA) is a neurological condition characterized by episodes of sudden, uncontrollable, and inappropriate laughing or crying. It is often associated with various neurological disorders and can significantly impact the quality of life of affected individuals.
==Signs and Symptoms==
Pseudobulbar affect is primarily marked by episodes of involuntary emotional expression, which are disproportionate or inappropriate to the social context. The key symptoms include:


[[File:PBA is not depression.png|thumb|525px|Several criteria exist to differentiate between PBA and depression.]]
* Sudden, uncontrollable episodes of [[laughter]] or [[crying]].
{{DISPLAYTITLE:Pseudobulbar Affect}}
* Emotional expression that is exaggerated or incongruent with the individual's actual emotional state.
'''Pseudobulbar Affect''' ('''PBA'''), also known as '''emotional incontinence''', is an emotional disturbance characterized by uncontrollable episodes of crying and/or laughing, or other emotional displays. PBA typically occurs as a secondary condition to a neurologic disorder or brain injury.
* Episodes that may occur several times a day and last from seconds to minutes.


== Signs and Symptoms ==
==Causes==
The main feature of PBA is a pathologically lowered threshold for exhibiting laughter, crying, or both. Affected individuals exhibit episodes of these emotional displays without an apparent motivating stimulus or in response to stimuli that would not have elicited such a response prior to the onset of their underlying neurologic disorder. Some patients may have emotional responses that are exaggerated in intensity but congruent with the character of the emotional display.
Pseudobulbar affect is typically associated with neurological conditions that affect the brain's ability to regulate emotions. Common causes include:


However, in other patients, the emotional display can be incongruent with, or even contradictory to, the emotional valence of the provoking stimulus. PBA symptoms can be severe, with persistent and unremitting episodes. Characteristics of PBA episodes include:
* [[Amyotrophic lateral sclerosis]] (ALS)
* [[Multiple sclerosis]] (MS)
* [[Stroke]]
* [[Traumatic brain injury]] (TBI)
* [[Alzheimer's disease]] and other forms of [[dementia]]
* [[Parkinson's disease]]


* Sudden and unpredictable onset
The exact pathophysiology of PBA is not fully understood, but it is believed to involve disruption of neural pathways that control emotional expression, particularly those involving the [[cerebellum]], [[brainstem]], and [[frontal lobes]].
* Typical duration of a few seconds to several minutes
* Occurrence of multiple episodes per day
== Social Impact ==
PBA can significantly affect individuals' social functioning and relationships with others. Sudden, frequent, extreme, and uncontrollable emotional outbursts may lead to social withdrawal and interfere with daily living, social and professional pursuits, and overall healthcare.


== Differentiating PBA from Depression ==
==Diagnosis==
PBA is often misdiagnosed as clinical depression, but there are clear distinctions between the two. In depression and grief syndromes, crying is typically a sign of sadness, while the pathological displays of crying in PBA are often in contrast to the underlying mood or greatly excessive. Additionally, PBA episodes are sudden and brief, whereas crying in depression is more sustained and closely related to the underlying mood state. The level of control one has over the crying episodes in PBA is minimal or nonexistent, while in depression, emotional expression can be modulated by the situation.
Diagnosing pseudobulbar affect involves a thorough clinical evaluation. Key steps in the diagnostic process include:


In some cases, depressed mood and PBA may co-exist. Depression is a common emotional change in patients with neurodegenerative diseases or post-stroke sequelae, often comorbid with PBA. However, comorbidity implies that depression is distinct from PBA and is not necessary for, nor does it exclude, a diagnosis of PBA.
* Detailed patient history to identify the frequency, duration, and triggers of emotional episodes.
* Neurological examination to assess for underlying neurological disorders.
* Use of standardized questionnaires, such as the [[Center for Neurologic Study-Lability Scale]] (CNS-LS), to quantify the severity of symptoms.


== Causes ==
==Treatment==
The specific pathophysiology involved in PBA is still under investigation, and the primary pathogenic mechanisms remain controversial. PBA is a secondary condition that occurs due to neurological diseases or brain injuries, resulting from disruptions of neural networks controlling the generation and regulation of emotions. PBA is commonly observed in individuals with neurologic injuries, such as traumatic brain injury (TBI) and stroke, and neurologic diseases like Alzheimer's disease, attention deficit/hyperactivity disorder
Treatment of pseudobulbar affect focuses on managing symptoms and improving quality of life. Options include:
(ADHD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and PANDAS in children and adults. PBA may also be reported as a symptom of hyperthyroidism, Graves' Disease, or hypothyroidism in combination with depression.


PBA has been associated with various other brain disorders, including brain tumors, Wilson's disease, syphilitic pseudobulbar palsy, and different types of encephalitis. Rarer conditions linked to PBA are gelastic epilepsy, dacrystic epilepsy, central pontine myelinolysis, olivopontinocerebellar atrophy, lipid storage diseases, chemical exposure (e.g., nitrous oxide and insecticides), fou rire prodromique, and Angelman syndrome.
* '''Medication''': The FDA-approved combination of [[dextromethorphan]] and [[quinidine]] (Nuedexta) is commonly used to reduce the frequency and severity of episodes. Other medications, such as [[antidepressants]], may also be prescribed.
* '''Behavioral therapy''': Cognitive-behavioral therapy (CBT) can help patients develop coping strategies to manage emotional episodes.
* '''Supportive care''': Education and support for patients and caregivers to understand the condition and its impact.


These primary neurologic injuries and diseases are hypothesized to affect chemical signaling in the brain, which in turn disrupts the neurologic pathways controlling emotional expression.
==Prognosis==
The prognosis for individuals with pseudobulbar affect varies depending on the underlying neurological condition. While PBA itself is not life-threatening, it can lead to social embarrassment, isolation, and [[depression]]. Effective management of symptoms can improve social functioning and quality of life.


== Diagnosis ==
==See Also==
A psychiatrist may diagnose PBA when a subject is crying or laughing uncontrollably for approximately 3–5 minutes without an apparent reason.
* [[Emotional lability]]
* [[Neurological disorder]]
* [[Mood disorder]]


== Treatment ==
==External Links==
Educating patients, families, and caregivers is crucial for the appropriate treatment of PBA. Crying associated with PBA might be misinterpreted as depression, and laughter may cause embarrassment. It is essential for families and caregivers to recognize the pathological nature of PBA and reassure patients that it is an involuntary syndrome that can be managed. Traditionally, antidepressants such as sertraline, fluoxetine, citalopram, nortriptyline, and amitriptyline have been prescribed with some efficacy.
* [Pseudobulbar Affect Foundation]
* [National Institute of Neurological Disorders and Stroke]


=== Medication ===
{{Neurology}}
Dextromethorphan hydrobromide affects the signals in the brain that trigger the cough reflex. It is used as a cough suppressant, although it can sometimes be used medicinally as a pain reliever and recreationally as a drug. Quinidine sulfate affects the way the heart beats and is generally used in people with certain heart rhythm disorders. It is also used to treat malaria. Quinidine sulfate, as a metabolic inhibitor, "increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan," enabling therapeutic dextromethorphan concentrations.
{{Psychiatry}}
* Dextromethorphan/quinidine is a combination of these two generic drugs and is the first FDA-approved drug for the treatment of PBA, approved on October 29, 2010.
* Quinidine sulfate affects the way the heart beats, and is generally used in people with certain heart rhythm disorders. It is also used to treat malaria. Quinidine sulfate, as a metabolic inhibitor, "increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan," enabling therapeutic dextromethorphan concentrations.
* Dextromethorphan/quinidine is a combination of these two generic drugs, and is the first FDA-approved drug for the treatment of PBA, approved on October 29, 2010.
{{stub}}
==External links==
* [http://www.stroke.org/site/DocServer/SCU_-_Jan-Feb_2005.pdf?docID=5161 "Pseudobulbar affect and stroke"] on the National Stroke Association website
{{Medical resources
| ICD10          = {{ICD10|F48.8}}
| ICD10CM        = {{ICD10CM|F48.2}}
| ICD9          = {{ICD9|310.81}}
| ICDO          =
| OMIM          =
| DiseasesDB    =
| MedlinePlus    =
| eMedicineSubj  =
| eMedicineTopic =
| MeshID        =
}}


[[Category:Neurological disorders]]
[[Category:Neurology]]
[[Category:Medical signs]]
[[Category:Psychiatric disorders]]
[[Category:Psychopathology]]
[[Category:Symptoms and signs: Cognition, perception, emotional state]]

Revision as of 21:29, 1 January 2025

Pseudobulbar Affect
Synonyms N/A
Pronounce N/A
Specialty N/A
Symptoms Involuntary laughing or crying
Complications Social embarrassment, depression
Onset
Duration
Types N/A
Causes Neurological disorders
Risks
Diagnosis Clinical evaluation
Differential diagnosis N/A
Prevention N/A
Treatment Medication, therapy
Medication N/A
Prognosis N/A
Frequency
Deaths N/A


Pseudobulbar affect (PBA) is a neurological condition characterized by episodes of sudden, uncontrollable, and inappropriate laughing or crying. It is often associated with various neurological disorders and can significantly impact the quality of life of affected individuals.

Signs and Symptoms

Pseudobulbar affect is primarily marked by episodes of involuntary emotional expression, which are disproportionate or inappropriate to the social context. The key symptoms include:

  • Sudden, uncontrollable episodes of laughter or crying.
  • Emotional expression that is exaggerated or incongruent with the individual's actual emotional state.
  • Episodes that may occur several times a day and last from seconds to minutes.

Causes

Pseudobulbar affect is typically associated with neurological conditions that affect the brain's ability to regulate emotions. Common causes include:

The exact pathophysiology of PBA is not fully understood, but it is believed to involve disruption of neural pathways that control emotional expression, particularly those involving the cerebellum, brainstem, and frontal lobes.

Diagnosis

Diagnosing pseudobulbar affect involves a thorough clinical evaluation. Key steps in the diagnostic process include:

  • Detailed patient history to identify the frequency, duration, and triggers of emotional episodes.
  • Neurological examination to assess for underlying neurological disorders.
  • Use of standardized questionnaires, such as the Center for Neurologic Study-Lability Scale (CNS-LS), to quantify the severity of symptoms.

Treatment

Treatment of pseudobulbar affect focuses on managing symptoms and improving quality of life. Options include:

  • Medication: The FDA-approved combination of dextromethorphan and quinidine (Nuedexta) is commonly used to reduce the frequency and severity of episodes. Other medications, such as antidepressants, may also be prescribed.
  • Behavioral therapy: Cognitive-behavioral therapy (CBT) can help patients develop coping strategies to manage emotional episodes.
  • Supportive care: Education and support for patients and caregivers to understand the condition and its impact.

Prognosis

The prognosis for individuals with pseudobulbar affect varies depending on the underlying neurological condition. While PBA itself is not life-threatening, it can lead to social embarrassment, isolation, and depression. Effective management of symptoms can improve social functioning and quality of life.

See Also

External Links

  • [Pseudobulbar Affect Foundation]
  • [National Institute of Neurological Disorders and Stroke]


edit 

WikiMD neurology


Psychiatry
Subspecialties
Organizations
Related topics
Lists
Retrieved from "https://wikimd.com/index.php?title=Pseudobulbar_affect&oldid=6089995"